GLYC vs. AEON, CELU, GNLX, RLYB, LTRN, SNGX, THTX, LPTX, RMTI, and MURA
Should you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include AEON Biopharma (AEON), Celularity (CELU), Genelux (GNLX), Rallybio (RLYB), Lantern Pharma (LTRN), Soligenix (SNGX), Theratechnologies (THTX), Leap Therapeutics (LPTX), Rockwell Medical (RMTI), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical preparations" industry.
GlycoMimetics (NASDAQ:GLYC) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
GlycoMimetics has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.
GlycoMimetics received 310 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 62.38% of users gave GlycoMimetics an outperform vote.
AEON Biopharma's return on equity of 0.00% beat GlycoMimetics' return on equity.
In the previous week, GlycoMimetics had 8 more articles in the media than AEON Biopharma. MarketBeat recorded 8 mentions for GlycoMimetics and 0 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 0.00 beat GlycoMimetics' score of -0.38 indicating that AEON Biopharma is being referred to more favorably in the news media.
GlycoMimetics presently has a consensus price target of $10.00, suggesting a potential upside of 3,785.00%. AEON Biopharma has a consensus price target of $6.00, suggesting a potential upside of 257.14%. Given GlycoMimetics' higher possible upside, equities analysts clearly believe GlycoMimetics is more favorable than AEON Biopharma.
AEON Biopharma has lower revenue, but higher earnings than GlycoMimetics.
75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 20.0% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
GlycoMimetics and AEON Biopharma tied by winning 7 of the 14 factors compared between the two stocks.
Get GlycoMimetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlycoMimetics Competitors List
Related Companies and Tools
